Literature DB >> 24741106

Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.

Roland Züst1, Ying-Xiu Toh2, Iris Valdés3, Daniela Cerny2, Julia Heinrich4, Lisset Hermida3, Ernesto Marcos3, Gerardo Guillén3, Ulrich Kalinke4, Pei-Yong Shi5, Katja Fink2.   

Abstract

UNLABELLED: Dengue virus (DENV) infects an estimated 400 million people every year, causing prolonged morbidity and sometimes mortality. Development of an effective vaccine has been hampered by the lack of appropriate small animal models; mice are naturally not susceptible to DENV and only become infected if highly immunocompromised. Mouse models lacking both type I and type II interferon (IFN) receptors (AG129 mice) or the type I IFN receptor (IFNAR(-/-) mice) are susceptible to infection with mouse-adapted DENV strains but are severely impaired in mounting functional immune responses to the virus and thus are of limited use for study. Here we used conditional deletion of the type I IFN receptor (IFNAR) on individual immune cell subtypes to generate a minimally manipulated mouse model that is susceptible to DENV while retaining global immune competence. Mice lacking IFNAR expression on CD11c(+) dendritic cells and LysM(+) macrophages succumbed completely to DENV infection, while mice deficient in the receptor on either CD11c(+) or LysM(+) cells were susceptible to infection but often resolved viremia and recovered fully from infection. Conditional IFNAR mice responded with a swift and strong CD8(+) T-cell response to viral infection, compared to a weak response in IFNAR(-/-) mice. Furthermore, mice lacking IFNAR on either CD11c(+) or LysM(+) cells were also sufficiently immunocompetent to raise a protective immune response to a candidate subunit vaccine against DENV-2. These data demonstrate that mice with conditional deficiencies in expression of the IFNAR represent improved models for the study of DENV immunology and screening of vaccine candidates. IMPORTANCE: Dengue virus infects 400 million people every year worldwide, causing 100 million clinically apparent infections, which can be fatal if untreated. Despite many years of research, there are no effective vaccine and no antiviral treatment available for dengue. Development of vaccines has been hampered in particular by the lack of a suitable small animal model. Mouse models used to test dengue vaccine are deficient in interferon (IFN) type I signaling and severely immunocompromised and therefore likely not ideal for the testing of vaccines. In this study, we explored alternative models lacking the IFN receptor only on certain cell types. We show that mice lacking the IFN receptor on either CD11c- or LysM-expressing cells (conditional IFNAR mice) are susceptible to dengue virus infection. Importantly, we demonstrate that conditional IFN receptor knockout mice generate a better immune response to live virus and a candidate dengue vaccine compared to IFNAR mice and are resistant to subsequent challenge.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24741106      PMCID: PMC4054447          DOI: 10.1128/JVI.03827-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Dengue.

Authors:  Cameron P Simmons; Jeremy J Farrar; van Vinh Chau Nguyen; Bridget Wills
Journal:  N Engl J Med       Date:  2012-04-12       Impact factor: 91.245

2.  Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor.

Authors:  Susana Orozco; Michael A Schmid; Poornima Parameswaran; Ruben Lachica; Matthew R Henn; Robert Beatty; Eva Harris
Journal:  J Gen Virol       Date:  2012-07-18       Impact factor: 3.891

3.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

4.  Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice.

Authors:  Tyler R Prestwood; Malika M Morar; Raphaël M Zellweger; Robyn Miller; Monica M May; Lauren E Yauch; Steven M Lada; Sujan Shresta
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

5.  A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice.

Authors:  Grace K Tan; Jowin K W Ng; Scott L Trasti; Wouter Schul; George Yip; Sylvie Alonso
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

6.  Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes.

Authors:  Meihui Xu; Vey Hadinoto; Ramapraba Appanna; Klas Joensson; Ying Xiu Toh; Thavamalar Balakrishnan; Swee Hoe Ong; Lucile Warter; Yee Sin Leo; Cheng-I Wang; Katja Fink
Journal:  J Immunol       Date:  2012-11-14       Impact factor: 5.422

7.  Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.

Authors:  Ernesto Marcos; Lázaro Gil; Laura Lazo; Alienys Izquierdo; Enma Brown; Edith Suzarte; Iris Valdés; Angélica García; Lissandra Méndez; María G Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Arch Virol       Date:  2012-09-18       Impact factor: 2.574

8.  Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.

Authors:  Raphaël M Zellweger; Robyn Miller; William E Eddy; Laura J White; Robert E Johnston; Sujan Shresta
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

9.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962

10.  Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques.

Authors:  Roland Züst; Hongping Dong; Xiao-Feng Li; David C Chang; Bo Zhang; Thavamalar Balakrishnan; Ying-Xiu Toh; Tao Jiang; Shi-Hua Li; Yong-Qiang Deng; Brett R Ellis; Esther M Ellis; Michael Poidinger; Francesca Zolezzi; Cheng-Feng Qin; Pei-Yong Shi; Katja Fink
Journal:  PLoS Pathog       Date:  2013-08-01       Impact factor: 6.823

View more
  43 in total

1.  Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation.

Authors:  Lindsey E Cook; Marissa C Locke; Alissa R Young; Kristen Monte; Matthew L Hedberg; Raeann M Shimak; Kathleen C F Sheehan; Deborah J Veis; Michael S Diamond; Deborah J Lenschow
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.

Authors:  Chao Shan; Xuping Xie; Jing Zou; Roland Züst; Bo Zhang; Rebecca Ambrose; Jason Mackenzie; Katja Fink; Pei-Yong Shi
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

3.  Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.

Authors:  Angela M Fowler; William W Tang; Matthew P Young; Anila Mamidi; Karla M Viramontes; Melanie D McCauley; Aaron F Carlin; Robert T Schooley; Jesica Swanstrom; Ralph S Baric; Jennifer Govero; Michael S Diamond; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2018-11-14       Impact factor: 21.023

4.  Type I interferon signaling enhances CD8+ T cell effector function and differentiation during murine gammaherpesvirus 68 infection.

Authors:  Ryan N Jennings; Jason M Grayson; Erik S Barton
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

Review 5.  Mouse models of dengue virus infection for vaccine testing.

Authors:  Vanessa V Sarathy; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

6.  Elevated sodium chloride drives type I interferon signaling in macrophages and increases antiviral resistance.

Authors:  Wu-Chang Zhang; Lin-Juan Du; Xiao-Jun Zheng; Xiao-Qing Chen; Chaoji Shi; Bo-Yan Chen; Xue-Nan Sun; Chao Li; Yu-Yao Zhang; Yan Liu; Hui Xiao; Qibin Leng; Xinquan Jiang; Zhiyuan Zhang; Shuyang Sun; Sheng-Zhong Duan
Journal:  J Biol Chem       Date:  2017-12-04       Impact factor: 5.157

Review 7.  Vaccines licensed and in clinical trials for the prevention of dengue.

Authors:  J Torresi; G Ebert; M Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

8.  CD8+ T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection.

Authors:  Huarong Huang; Shihua Li; Yongli Zhang; Xiaojuan Han; Baoqian Jia; Hongtao Liu; Dandan Liu; Shuguang Tan; Qihui Wang; Yuhai Bi; William J Liu; Baidong Hou; George Fu Gao; Fuping Zhang
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

Review 9.  Genetic Dissection of the Host Tropism of Human-Tropic Pathogens.

Authors:  Florian Douam; Jenna M Gaska; Benjamin Y Winer; Qiang Ding; Markus von Schaewen; Alexander Ploss
Journal:  Annu Rev Genet       Date:  2015-09-25       Impact factor: 16.830

10.  Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees.

Authors:  Sumathy Velumani; Ying Xiu Toh; Shobana Balasingam; Sophia Archuleta; Yee Sin Leo; Victor C Gan; Tun Linn Thein; Annelies Wilder-Smith; Katja Fink
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.